Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
about
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studyEquipoise, design bias, and randomized controlled trials: the elusive ethics of new drug developmentAcquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDsDevelopment of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalphaUse of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trialA non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeksArtesunate influences Th17/Treg lymphocyte balance by modulating Treg apoptosis and Th17 proliferation in a murine model of rheumatoid arthritis.Abatacept treatment for rheumatoid arthritisSelection bias in rheumatic disease research.Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis.Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.Combination treatment strategies in early rheumatoid arthritis.A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquineTransition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis.Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatmentMultidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview.Sulphasalazine inhibits human antigen-specific immune responses in vivo.Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.Antimetabolites in the treatment of arthritis: current status of the use of antimetabolites.Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis.Pharmacological management of transient synovitis.Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities.Making smart investment decisions in clinical researchValidation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registryCombination therapy for rheumatoid arthritis in the era of biologicalsEvolution of clinical pharmacy in the practice of rheumatology.Rheumatoid arthritis--early diagnosis and disease managementAntibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis.Potent Antiarthritic Properties of Phloretin in Murine Collagen-Induced Arthritis.Therapeutic options for rheumatoid arthritis.Rheumatoid arthritis therapy: advances from bench to bedside.Discussion: DMARDs and biologic therapies in the management of inflammatory joint diseases.Fish oil and rheumatoid arthritis: past, present and future.Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.
P2860
Q24674942-B1C3EDE4-9BFC-4D11-94BA-567F5E969D50Q24800828-ADD27CA4-D98A-4DEE-982E-FED074CBE532Q28394186-EB496225-1C1B-47F6-9DFB-ACE53EFA6F89Q28394197-7AF66291-A86C-437A-9D37-FFA0EB9489CBQ33470696-8D1A080E-BC92-479B-BFCC-475C8F5FD946Q33659050-3BC1D4A8-7E20-4FD5-A70B-7835E8F1E9E2Q33723953-6A41349D-7BA7-426C-9184-915596CF1812Q34588972-084B6656-F84C-4B48-A73E-ECA89DCB866BQ34662693-81D17B92-6E4D-4BEB-8238-DCB242ED9C60Q35084199-F961F581-4AD4-4CC8-99FE-31674929E917Q35216972-6E5E4774-6FF6-40BE-9A34-DCAA5F6E2236Q35552265-296F6D4D-34B7-4C92-B0EE-43BA0ED30A1AQ35556077-6F0651F5-E0C8-4BC5-A12A-67D8C874B6A1Q35557430-5D0BB742-68EC-461E-AB2C-31D37B1BE645Q35567825-A8EB14EF-76D5-456A-BE25-D6CF12D453D9Q35605474-429D3EA5-F68A-4462-A344-817E21181C01Q35638735-CC745426-38F6-453B-ABDA-0F539D7502A0Q35744255-17AEC3C1-7690-4159-BF78-AD7523B6A728Q35760185-1D2350C3-6724-42EC-AFC6-27651D57782FQ35953319-562C8C29-5F37-4AA6-83D9-CED961CE8CEDQ35967177-AC6CD0A3-EADF-495D-AC17-4521DCA605D0Q36013828-63EE24A1-7330-45EB-873E-F88F45B3825CQ36150612-D858C340-759B-49C9-83C2-105A06716542Q36349593-7449C139-F1E2-4ED2-B09D-E4DB5C0A1A09Q36408155-1DFF8CC9-E679-4C93-8FE9-8A219C77B70EQ36409914-D8DED748-BBEA-47E4-9E2D-66D3FE2E17AEQ36623126-E87422D1-4E72-47AF-A1DF-4F2AD7047723Q36625596-B25C5D71-4846-462E-88D1-65F68F847101Q36668191-08B24487-AA09-4CDA-8ED7-F1C4728D6966Q36823684-970D34F0-8C1A-4A16-A442-B4799C5BA57AQ36937540-BF661E66-C232-4E4A-87F9-E4BF4348FD23Q37043713-C8CC90BE-A752-4A28-8435-35FCEA7426C6Q37356818-28898D02-D38C-4D6E-BF7F-0CB61D8AF9BDQ37511903-9118EFAF-A8E5-447C-AFEB-8CC15202B123Q37552947-5C304574-EA42-43EE-A037-A1992F3D3CA1Q37739480-963D504C-0F5A-4344-AEDB-C329B71D5F3DQ37754640-BA6C49A7-4B46-444C-B67D-EE32BCF54F20Q37761399-D59067A4-C435-488D-8146-3D6D4EB45D54Q37854742-1F165927-4E4A-468F-8501-0DFAEB202AB8Q38020459-F2C4E28E-E089-4C86-B19D-5022292F7194
P2860
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@en
type
label
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@en
prefLabel
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@en
P2093
P2860
P356
P1476
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@en
P2093
Ana Fernandez
Claire Haire
Gail Paulsen
Gerald Moore
Jack Mallek
James R O'Dell
Jeffrey Felt
Julie Stoner
Kent Blakely
Lynell Klassen
P2860
P304
P356
10.1002/ART.10228
P577
2002-05-01T00:00:00Z